Corticosteroid therapy for nephrotic syndrome in children

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 8, 2020, Pages

  Hahn, Deirdre ^a   Samuel, Susan M ^b   Willis, Narelle S ^a,c   Craig, Jonathan C ^a,d   Hodson, Elisabeth M ^a,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM; CALCIUM CARBONATE; CORTICOSTEROID; DEFLAZACORT; ENALAPRIL; HYDROCORTISONE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; SAIREI TO; VITAMIN D;

CATARACT; CHILD; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EYE DISEASE; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERTENSION; INFECTION; LOADING DRUG DOSE; LOW DRUG DOSE; MENTAL DISEASE; MOON FACE; MORNING DOSAGE; NEPHROTIC SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; META ANALYSIS;

EID: 85090551764     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001533.pub6     Document Type: Review

References (157)

1. Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Archives of Disease in Childhood 2008;93(3):226-8. x-wiley/crsRef/3229752 [MEDLINE: 17573408]
2. Abeyagunawardena A, Thalgahagoda S, Illangasekera Y, Trompeter R. A short course of prednisolone during an upper respiratory tract infection reduces the risk of relapse in childhood nephrotic syndrome [abstract no: P12]. Pediatric Nephrology 2014;29(9):1689. x-wiley/crsRef/14429770 [EMBASE: 71662409]
3. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, et al. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatric Nephrology 2017;32(8):1377-82. x-wiley/crsRef/14429771 [MEDLINE: 28341877]
4. Abeyagunawardena AS, Thalgahagoda S, Illangasekera Y, Trompeter RS. Short course of daily prednisolone during upper respiratory tract infection reduces the risk of relapse in childhood nephrotic syndrome [abstract no: G376(P)]. Archives of Disease in Childhood 2014;99(Suppl 1):A155-6. x-wiley/crsRef/3229755 [EMBASE: 71566356]
5. Agarwal I, Gemson JA, Moses PD, Mathew L, Prashanth P. Open randomized clinical study to evaluate efficacy and safety of deflazacort versus prednisolone in idiopathic nephrotic syndrome [abstract no: 558]. Pediatric Nephrology 2010;25(9):1906. x-wiley/crsRef/14429773 [EMBASE: 70438660]
6. Al Talhi A, Al Saran K, Osman ET, Al Shatri A, Osman M, Mirza K. A randomized study on a 3-month versus a 7-month prednisolone regimen for the initial episode of childhood idiopathic nephrotic syndrome at a large Saudi center. International Journal of Pediatrics & Adolescent Medicine 2018;5(1):18-23. x-wiley/crsRef/14429775 [EMBASE: 620760413]
7. Anand P, Pruthi PK, Anand K. Standard versus long term corticosteroid therapy in the treatment of initial episode of nephrotic syndrome in children [abstract no: P-SUN228]. Pediatric Nephrology 2013;28(8):1609-10. x-wiley/crsRef/14429777 [EMBASE: 620760413]
8. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbeitsgemeinschaft fur Padiatrische Nephrologie". European Journal of Pediatrics 1981;135(3):229-37. x-wiley/crsRef/3229757 [MEDLINE: 7227377]
9. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft fur Padiatrische Nephrologie". Lancet 1979;1(8113):401-3. x-wiley/crsRef/3229758 [MEDLINE: 84259]
10. Brodehl J, Krohn HP. Steroid trial in frequently relapsing nephrotic syndrome in children. In: Glomerulonephritis. International Conference on Pathogenesis, Pathology and Treatment. New York: Wiley, 1977:210-5. x-wiley/crsRef/3229759
11. Brodehl J, Krohn HP, Ehrich JH. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Klinische Padiatrie 1982;194(3):162-5. x-wiley/crsRef/3229762 [MEDLINE: 6752557]
12. Ehrich JH, Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Initial treatment of idiopathic nephrotic syndrome: short vs standard prednisone [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:59. [CENTRAL: CN-00644361] x-wiley/crsRef/3229764
13. Ehrich JH, Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Short initial prednisone therapy versus standard prednisone therapy in the steroid responsive nephrotic syndrome [abstract no: F5-1]. Pediatric Nephrology 1987;1(1):C28. [CENTRAL: CN-00445202] x-wiley/crsRef/3229763
14. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet 1988;1(8582):380-3. x-wiley/crsRef/3229761 [MEDLINE: 2893190]
15. Ehrich JH, Arbeitsgemeinschaft fur Padiatrische Nephrologie. Minimal change nephrotic syndrome: long prednisone therapy vs standard prednisone therapy [abstract]. Nephrology Dialysis Transplantation 1991;6(10):771. [CENTRAL: CN-00260613] x-wiley/crsRef/3229766
16. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. European Journal of Pediatrics 1993;152(4):357-61. x-wiley/crsRef/3229767 [MEDLINE: 8482290]
17. Bagga A, Hari P, Srivastava RN. Long (LP) versus standard (SP) initial prednisolone treatment for idiopathic nephrotic syndrome (NS) [abstract no: P225]. Pediatric Nephrology 1998;12(1):C155. [CENTRAL: CN-00583944] x-wiley/crsRef/3229774
18. Bagga A, Hari P, Srivastava RN. Long (LP) versus standard (SP) initial prednisolone treatment for nephrotic syndrome (NS) [abstract no: FP23]. In: 3rd Congress. Nephrology Urology Transplantation Society (NUTS) of SAARC; 1999 Feb 18 - 21; Colombo, Sri Lanka. 1999:158. [CENTRAL: CN-00460325] x-wiley/crsRef/3229775
19. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatric Nephrology 1999;13(9):824-7. x-wiley/crsRef/3229776 [MEDLINE: 10603129]
20. Basu B, Bhattacharyya S, Barua S, Naskar A, Roy B. Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome. Clinical & Experimental Nephrology 2020;24(7):622-9. x-wiley/crsRef/14429779 [MEDLINE: 32201918]
21. Borovitz Y, Alfandary H, Haskin O, Levi S, Kaz S, Davidovits M, et al. Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study. European Journal of Pediatrics 2020;179(2):279-83. x-wiley/crsRef/14429781 [MEDLINE: 31728673]
22. Borovitz Y, Haskin O, Levi S, Kaz S, Alfandary H, Davidovits M, et al. Lower prednisone dosing for nephrotic syndrome relapse: a prospective randomized study [abstract no: O-07]. Pediatric Nephrology 2017;32(9):1647. x-wiley/crsRef/14429782 [EMBASE: 618119422]
23. Broyer M, Terzi F, Gagnadoux MF, Guest G, Niaudet P. A randomized double blind study of deflazacort (D) versus prednisone (P) in the treatment of idiopathic nephrotic syndrome (INS) [abstract no: 1548]. Journal of the American Society of Nephrology 1995;6(3):414. [CENTRAL: CN-00483349] x-wiley/crsRef/3229778
24. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatric Nephrology 1997;11(4):418-22. x-wiley/crsRef/3229779 [MEDLINE: 9260237]
25. Bagga A, Ekka BK, Srivastava RN. Single versus divided dose prednisolone therapy for relapses of nephrotic syndrome (NS) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A113. [CENTRAL: CN-00261391] x-wiley/crsRef/3229781
26. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatric Nephrology 1997;11(5):597-9. x-wiley/crsRef/3229782 [MEDLINE: 9323286]
27. Gulati A, Math A, Sreenivas V, Hari P, Bagga A. Administration of daily corticosteroids prevents infection-associated relapses in frequently relapsing NS [abstract]. Clinical Nephrology 2010;74(7 Suppl 1):S158-9. x-wiley/crsRef/14429784 [EMBASE: 70344148]
28. Gulati A, Math A, Sreeniwas V, Hari P, Bagga A. Administration of daily corticosteroids prevents infection associated relapses in frequently relapsing nephrotic syndrome [abstract no: SU714]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. x-wiley/crsRef/14429785
29. Gulati A, Sinha A, Hari P, Bagga A. Efficacy of daily corticosteroids to prevent infection associated relapses in frequently relapsing nephrotic syndrome: A randomized controlled trial [abstract]. Pediatric Nephrology 2010;25(9):1874. x-wiley/crsRef/14429786 [EMBASE: 70438498]
30. Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(1):63-9. x-wiley/crsRef/14429787 [MEDLINE: 20847092]
31. Hiraoka M, Sudo M, West Japanese Cooperative Study of Kidney Disease in Children. Low versus standard dosage of prednisolone for initial treatment of idiopathic nephrotic syndrome in children [abstract no: A0445]. Journal of the American Society of Nephrology 1996;7(9):1335. x-wiley/crsRef/3229787
32. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Kidney International 2000;58(3):1247-52. x-wiley/crsRef/3229788 [MEDLINE: 10972687]
33. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, et al. Older boys benefit from intensive initial prednisolone therapy for nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):103A. [CENTRAL: CN-00550605] x-wiley/crsRef/3229789
34. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases 2003;41(6):1155-62. x-wiley/crsRef/3229791 [MEDLINE: 12776266]
35. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. British Medical Journal Clinical Research Ed 1985;291(6505):1305-8. x-wiley/crsRef/3229793 [MEDLINE: 3933645]
36. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children. Journal of Pediatrics 1979;95(2):239-43. x-wiley/crsRef/3229795 [MEDLINE: 109598]
37. Jayantha UK. Comparison of ISKDC regime with a 7 months steroid regime in the first attack of nephrotic syndrome [abstract no: OPFC26]. Pediatric Nephrology 2004;19(9):C81. [CENTRAL: CN-00583710] x-wiley/crsRef/3229797
38. Jayantha UK. Comparison of ISKDC regime with a six month steroid regime in the treatment of steroid sensitive nephrotic syndrome. Data on file 2002. x-wiley/crsRef/3229799
39. Jayantha UK. Comparison of ISKDC regime with a six month steroid regime in the treatment of steroid sensitive nephrotic syndrome [abstract no: FP2B]. In: 7th Asian Congress of Pediatric Nephrology; 2000 Nov 1-4; Singapore. 2000:28. [CENTRAL: CN-00583708] x-wiley/crsRef/3229798
40. Jayantha UK. Comparison of ISKDC regime with 6 month regime in patients with relapsing nephrotic syndrome. Data on file 2002. x-wiley/crsRef/3229801
41. Jayantha UK. Prolong versus standard steroid therapy for children with relapsing course of nephrotic syndrome [abstract no: P026]. Pediatric Nephrology 2004;19(9):C99. [CENTRAL: CN-00583706] x-wiley/crsRef/3229802
42. Kansal A, Mantan M, Yadav S. Effectiveness of a low dose prednisolone regimen for treatment of relapses in children with SSNS [abstract no: IPN10471- 84]. Pediatric Nephrology 2019;34(10):1871. x-wiley/crsRef/14429789
43. Kleinknecht C, Broyer M, Parchoux B, Loriat C, Nivet H, Palcoux JB, et al. Comparison of short and long treatment at onset of steroid sensitive nephrosis (SSN). Preliminary results of a multicenter controlled trial for the French Society of Pediatric Nephrology [abstract]. International Journal of Pediatric Nephrology 1982;3(1):45. [CENTRAL: CN-00550480] x-wiley/crsRef/3229804
44. Ksiazek J, Wyszynska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatrica 1995;84(8):889-93. x-wiley/crsRef/3229806 [MEDLINE: 7488812]
45. Leisti S, Koskimies O, Perheentupa J, Vilska J, Hallman N. Idiopathic nephrotic syndrome: prevention of early relapse. British Medical Journal 1978;1(6117):892. x-wiley/crsRef/3229808 [MEDLINE: 346147]
46. Li X, Li Z, Cheng Z. Treatment of children with simple nephrotic syndrom using prednison once per day. Acta Academiae Medicinae Hubei 1994;15(4):386-8. x-wiley/crsRef/3229810 [EMBASE: 1995005617]
47. Liern M, Dieguez S, Canepa C. Recovery of total immunoglobulin and immunoglobulin subclasses in nephrotic syndrome: deflazacort vs methylprednisone [Recuperacion de la inmnoglobulina total y sus subclases en el sindrome nefrotico: deflazacort vs metilprednisona]. Nefrologia 2008;28(5):563. x-wiley/crsRef/3229812 [MEDLINE: 18816222]
48. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron 2000;85(4):343-5. x-wiley/crsRef/3229814 [MEDLINE: 10940745]
49. Mishra OP, Thakur N, Mishra RN, Prasad R. Prolonged versus standard prednisolone therapy for initial episode of idiopathic nephrotic syndrome. Journal of Nephrology 2012;25(3):394-400. x-wiley/crsRef/3229816 [MEDLINE: 21928226]
50. Mocan H, Erduran E, Karaguzel G. High dose methylprednisolone therapy in nephrotic syndrome. Indian Journal of Pediatrics 1999;66(2):171-4. x-wiley/crsRef/3229818 [MEDLINE: 10798055]
51. Mocan H, Mocan MZ, Erduran E, Karaguzel G, Aslan Y. The effect of high dose methylprednisolone therapy in patients with minimal change nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A74. [CENTRAL: CN-00261380] x-wiley/crsRef/3229819
52. Moundekhel S, Khan GS, Afridi U. Management of nephrotic syndrome: ISKDC versus APN. Pakistan Journal of Medical & Health Sciences 2012;6(1):212-5. x-wiley/crsRef/14429791 [EMBASE: 368679233]
53. Norero C, Delucchi A, Lagos E, Rosati P. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children [Cuadro inicial del sindrome nefrosico primario del nino: evaluacion a 18 meses de dos esquemas de tratamiento con prednisona. Groupo Cooperativo Chileno de Estudio del Sindrome Nefrosico del Nino]. Revista Medica de Chile 1996;124(5):567-72. x-wiley/crsRef/3229821 [MEDLINE: 9035508]
54. Norero C, Delucchi A, Lagos E, Rosati P. Long term evaluation of two prednisone treatments in initial idiopathic nephrotic syndrome (INS) in children. Preliminary findings [abstract no: P135]. Pediatric Nephrology 1995;9(6):C88. [CENTRAL: CN-00550669] x-wiley/crsRef/3229822
55. Paul SK, Muinuddin G, Jahan S, Begum A, Rahman MH, Hossain MM. Long versus standard initial prednisolone therapy in children with idiopathic nephrotic syndrome. Mymensingh Medical Journal: MMJ 2014;23(2):261-7. x-wiley/crsRef/14429793 [MEDLINE: 24858152]
56. Pecoraro C, Caropreso MR, Malgieri G, Ferretti A, Nuzzi F. Therapy of first episode steroid responsive nephrotic syndrome (FESRNS): a randomised controlled trial [abstract no: MP087]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v230. [CENTRAL: CN-00644161] x-wiley/crsRef/3229824
57. Pecoraro C, Caropreso MR, Malgieri G, Ferretti AV, Raddi G, Piscitelli A, et al. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract no: OFC41]. Pediatric Nephrology 2004;19(9):C72. [CENTRAL: CN-00644160] x-wiley/crsRef/3229825
58. Pecoraro C, Caropreso MR, Passaro G, Ferretti AV, Malgieri G. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract no: M199]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):63. [CENTRAL: CN-00447140] x-wiley/crsRef/3229826
59. Webb N, Trompeter R, Cummins C, Wheatley K, Frew E. Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial [protocol]. PREDNOS Clinical Trial Protocol Version 2.1 2013 Sept 1. x-wiley/crsRef/14429795
60. Webb N, Wooley R, Brettell E, Cummins C, Trompeter R, Barsoum E, et al. Standard vs extended course prednisolone therapy for the presenting episode of steroid sensitive nephrotic syndrome: the PREDNOS study [abstract no: O-08]. Pediatric Nephrology 2017;32(9):1647-8. x-wiley/crsRef/14429796 [EMBASE: 618119435]
61. Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 2019;365:l1800. x-wiley/crsRef/14429797 [MEDLINE: 31335316]
62. Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, et al. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technology Assessment (Winchester, England) 2019;23(26):1-108. x-wiley/crsRef/14429798 [MEDLINE: 31156083]
63. Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, et al. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technology Assessment (Winchester, England) 2019;23(26):1-108. x-wiley/crsRef/14429800 [MEDLINE: 31156083]
64. Gargiulo A, Vivarelli M, Pecoraro C, Pennesi M, Pasini A, Edefonti A, et al. Short versus long courses of prednisone for the treatment of relapses of steroid sensitive nephrotic syndrome. results of the PROPINE study [abstract no: O-4]. Pediatric Nephrology 2018;33(10):1810. x-wiley/crsRef/14429802 [EMBASE: 618119435]
65. Raman V, Krishnamurthy S, Harichandrakumar KT. Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Pediatric Nephrology 2016;31(4):595-604. x-wiley/crsRef/14429804 [MEDLINE: 26759000]
66. Satomura K, Yamaoka K, Shima M, Tanaka Y, Ashino N, Nakagawa K, et al. Standard vs low initial dose of prednisolone therapy for first episodes of nephrotic syndrome in children [abstract no: P238]. Pediatric Nephrology 2001;16(8):C117. [CENTRAL: CN-00447593] x-wiley/crsRef/3229828
67. Gulati S, Ahmed M, Sharma RK, Gupta A, Pokhariyal S. Comparison of abrupt withdrawal versus slow tapering regimen of prednisolone therapy in the management of first episode of steroid responsive childhood idiopathic nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A87. [CENTRAL: CN-00445595] x-wiley/crsRef/14429806
68. Sharma RK, Ahmed M, Gulati S, Gupta A, Pokhariyal S. Comparison of abrupt withdrawal versus slow tapering regimen of prednisolone therapy in the management of first episode of steroid responsive childhood idiopathic nephrotic syndrome. Data on file 2002. x-wiley/crsRef/14429807
69. Sharma RK, Ahmed M, Gupta A, Gulati S, Sharma AP. Comparison of abrupt withdrawal versus slow tapering regimens of prednisolone therapy in management of first episode of steroid responsive childhood idiopathic nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):97A. [CENTRAL: CN-00550434] x-wiley/crsRef/14429808
70. Sheikh S, Mishra K, Kumar M. Low versus conventional dose prednisolone for nephrotic syndrome relapses: randomised-controlled, non-inferiority-trial [abstract no: IPN10923-86]. Pediatric Nephrology 2019;34(10):1980. x-wiley/crsRef/14429810
71. Singhal R, Pandit S, Dhawan N. Deflazacort versus prednisolone: randomized controlled trial in treatment of children with idiopathic nephrotic syndrome. Iranian Journal of Pediatrics 2015;25(2):e510. x-wiley/crsRef/14429812 [MEDLINE: 26196009]
72. Bagga A, Sinha A, Saha A, Kumar M, Afzal K, Mehta A. Randomized double blind, placebo controlled trial to compare the efficacy of 3-months versus 6-months therapy with prednisolone for the first episode of idiopathic nephrotic syndrome (CTRI/2010/091/001095) [abstract no: P139]. Pediatric Nephrology 2012;27(9):1707. x-wiley/crsRef/14429814 [EMBASE: 71386357]
73. Sinha A, Bagga A, Sharma S, Saha A, Kumar M, Afzal K, et al. Randomized, double blind, placebo controlled trial to compare the efficacy of 3-months versus 6-months therapy with prednisolone for the first episode of idiopathic nephritic syndrome [abstract no: O-40]. Pediatric Nephrology 2013;28(8):1361-2. x-wiley/crsRef/14429815 [EMBASE: 71126981]
74. Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid- sensitive nephrotic syndrome. Kidney International 2015;87(1):217-24. x-wiley/crsRef/14429816 [MEDLINE: 25029428]
75. Teeninga N, Guan Z, Stevens J, Kist-Van Holthe JE, Ackermans MT, van der Heijden AJ, et al. Population pharmacokinetics of prednisolone in relation to clinical outcome in children with nephrotic syndrome. Therapeutic Drug Monitoring 2016;38(4):534-45. x-wiley/crsRef/14429817 [EMBASE: 610346284]
76. Teeninga N, Kist-Van Holthe JE, De Mos NI, Peters N, Hop WC, van der Heijden AJ, et al. Optimal treatment of steroid sensitive nephrotic syndrome in children: a multicenter randomised controlled trial [abstract no: 450]. Pediatric Nephrology 2010;25(9):1884. x-wiley/crsRef/14429818 [EMBASE: 70438552]
77. Teeninga N, Kist-Van Holthe JE, De Mos NI, Van Rijswijk-Peeters N, Hop WC, Nauta J. Optimal treatment of steroid sensitive nephrotic syndrome in children: a randomised controlled trial [abstract no: P090]. Pediatric Nephrology 2008;23(9):1619. [CENTRAL: CN-01657514] x-wiley/crsRef/14429819
78. Teeninga N, Kist-van Holthe JE, van den Akker EL, Kersten MC, Boersma E, Krabbe HG, et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney International 2014;85(6):1444-53. x-wiley/crsRef/3229840 [MEDLINE: 24429396]
79. Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. Journal of the American Society of Nephrology 2013;24(1):149-59. x-wiley/crsRef/3229839 [MEDLINE: 23274956]
80. Teeninga N, Kist-Van Holthe JE, Van Ruswuk N, De Mos NI, Hop WC, Wetzels JF, et al. Effect of extended prednisolone treatment from three to six months, with equal cumulative doses, on childhood nephrotic syndrome: a nation-wide randomised controlled trial [abstract no: OP61]. Pediatric Nephrology 2012;27(9):1637-8. x-wiley/crsRef/3229838 [EMBASE: 71386208]
81. Ueda N, Chihara M, Kawaguchi S, Niimomi Y, Nonada T, Matsumoto J, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. Journal of Pediatrics 1988;112(1):122-6. x-wiley/crsRef/14429820 [MEDLINE: 3335948]
82. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Yasaki T. Intermittent versus long-term tapering prednisolone regimens as initial therapy in children with steroid-responsive nephrotic syndrome. [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:98. x-wiley/crsRef/14429821
83. Yadav M, Sinha A, Hari P, Bagga A. Efficacy of low-dose daily versus alternate day prednisone in children with frequently relapsing nephrotic syndrome (FRNS): open-label randomized controlled trial (RCT) [abstract no: FP-S25-09]. Pediatric Nephrology 2016;31(10):1752. x-wiley/crsRef/14429823 [EMBASE: 612479637]
84. Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Pediatric Nephrology 2019;34(5):829-35. x-wiley/crsRef/14429824 [MEDLINE: 30194663]
85. Ito H, Yoshikawa N. Multicenter controlled trial in nephrotic syndrome in Japanese children [abstract no: S-13.5]. In: 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 - Sep 4; Jerusalem, Israel. 1992:C37. x-wiley/crsRef/14429825
86. Nakanishi K, Iijima K, Ishikura K, Hataya H, Nakazato H, Sasaki S, et al. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(5):756-62. x-wiley/crsRef/14429826 [MEDLINE: 23371961]
87. Takekoshi Y. Treatment of idiopathic nephrotic syndrome [abstract no: S-1]. Pediatric Nephrology 1996;10(1):C3. [CENTRAL: CN-00402800] x-wiley/crsRef/3229844
88. Yoshikawa N, Ito H, Takehoshi Y, Honda M, Awazu M, Iijima K, et al. Standard versus long-term prednisolone with sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Nippon Jinzon Gakkai Shi [Japanese Journal of Nephrology] 1998;40(8):587-90. x-wiley/crsRef/3229845 [MEDLINE: 9893457]
89. Yoshikawa N, Nakanishi K, Oba MS, Sako M, Ohashi Y, Iijima K. Increased duration and dose of prednisolone (PSL) treatment does not reduce relapses in childhood nephrotic syndrome [abstract no: SA-PO1080]. Journal of the American Society of Nephrology 2014;24(Abstracts):3B. x-wiley/crsRef/14429828
90. Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney International 2015;87(1):225-32. x-wiley/crsRef/14429829 [MEDLINE: 25054775]
91. Zhang Y, Huang JP, Xiao HJ, Ding J, Yao Y, Yang JY. Prospective clinical randomized controlled trial of pulse methylprednisolone therapy in children with steroid sensitive nephrotic syndrome [abstract no: 797 (P)]. Pediatric Nephrology 2007;22(9):1609. [CENTRAL: CN-01912552] x-wiley/crsRef/14429831
92. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Results of the nephrotic syndrome study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Pediatric Nephrology 1999;13:C26. [CENTRAL: CN-00636143] x-wiley/crsRef/14429833 [CRSEF: 329770]
93. Hoyer PF, Brodehl J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. Journal of the American Society of Nephrology 2006;17(4):1151–7. x-wiley/crsRef/14429834 [MEDLINE: 16540560] [CRSREF: 3229771]
94. Hoyer PF, Arbeitsgemeinschaft fur Padiatrische Nephrologie. The initial treatment of idiopathic nephrotic syndrome with prednisone and cyclosporin A: preliminary results of a therapeutic trial [abstract no: P147]. Pediatric Nephrology 1995;9(6):C91. [CENTRAL: CN-00401335] x-wiley/crsRef/14429835 [CRSREF: 3229770]
95. Hoyer PF. Results of the Nephrotic Syndrome Study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):104A. [CENTRAL: CN-0055522] x-wiley/crsRef/14429836 [CRSREF:3229772]
96. Zhang B, Liu T, Wang W, Zhang X, Fan S, Liu Z, et al. A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome. European Journal of Pediatrics 2014;173(4):509-15. x-wiley/crsRef/14429838 [MEDLINE: 24240666] [CRSREF: 3229850]
97. Zhang BL, Liu T. A prospective clinical randomized controlled trial on azithromycin therapy in induction treatment in children with nephrotic syndrome [abstract no: O-44]. Pediatric Nephrology 2013;28(8):1364. x-wiley/crsRef/14429839 [EMBASE: 71126985]
98. Hari P. Efficacy of short prednisolone treatment for relapse in children with steroid sensitive nephrotic syndrome: a randomised controlled study. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12315 (first received 5 November 2015). x-wiley/crsRef/3229934
99. Kalra S. A randomized controlled clinical trial to compare the efficacy of standard dose of steroids vs reduced dose in treating relapses in children with steroid sensitive nephrotic syndrome. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=25815 (first received 3 May 2018). x-wiley/crsRef/14429841
100. Mishra K. A comparison of two doses of prednisolone for relapses in children with steroid sensitive nephrotic syndrome: a randomized controlled non inferiority trial. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26036 (first received 23 May 2018). x-wiley/crsRef/14429843
101. Webb NJ, Frew E, Brettell EA, Milford DV, Bockenhauer D, Saleem MA, et al. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial. Trials [Electronic Resource] 2014;15:147. x-wiley/crsRef/14429845 [MEDLINE: 24767719]
102. Schijvens A, Schreuder M. Steroid treatment reduction in relapsing childhood nephrotic syndrome: a new nationwide randomized controlled trial in the Netherlands - the RESTERN study [abstract no: P-163]. Pediatric Nephrology 2017;32(9):1729. x-wiley/crsRef/14429847 [EMBASE: 618120212]
103. Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JA, Bouts AH, et al. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 2017;7(9):e018148. x-wiley/crsRef/14429848 [MEDLINE: 28963315]
104. Sinha A, Gipson D, Wong C, Massengil S, Ahmad A, Hari P, et al. 6-months versus 3-months prednisolone for initial therapy of steroid sensitive nephrotic syndrome: open label RCT [abstract no: IPN11430-80]. Pediatric Nephrology 2019;34(10):2076. x-wiley/crsRef/14429850
105. Sinha A, Hari P, Bagga A. Randomized controlled trial to compare efficacy of 3-months versus 6-months therapy with prednisolone for the first episode of idiopathic nephrotic syndrome in children <4-yr-old [abstract no: PO-321]. Pediatric Nephrology 2016;31(10):1867-8. x-wiley/crsRef/14429851 [EMBASE: 612479470]
106. Arneil GC. Treatment of nephrosis with prednisolone. Lancet 1956;270(6920):409-11. [MEDLINE: 13307947]
107. Arneil GC. The nephrotic syndrome. Pediatric Clinics of North America 1971;18(2):547-59. [MEDLINE: 4945403]
108. Aydin M, Franke I, Kurylowicz L, Ganshow R, Lentze M, Born M, et al. The long-term outcome of childhood nephrotic syndrome in Germany: a cross sectional study. Clinical & Experimental Nephrology 2019;23(5):676-88. [MEDLINE: 30721392]
109. Beanlands H, Maione M, Poulton C, Herreshoff E, Hladunewich MA, Hailperin M, et al. Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome. Nephrology Dialysis Transplantation 2017;32(Suppl 1):i98-105. [MEDLINE: 28391342]
110. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatric Nephrology 1997;11(4):429-34. [MEDLINE: 9260239]
111. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629-39. [MEDLINE: 12944064]
112. Egger M, Dickersin K, Davey Smith G. Problems and limitations in conducting systematic reviews. In: Egger M, Davey Smith G, Altman D, editors(s). Systematic Reviews in Health care: Meta-analysis in context. Second edition. London: BMJ Publishing Group, 2001. [ISBN-13: 978-0727914880]
113. Gipson DS, Massengill SF, Yoa L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009;124(2):747-57. [MEDLINE: 19651590]
114. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International 2011;79(6):678-85. [MEDLINE: 21178977]
115. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
116. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: 21195583]
117. Guess A, Agrawal S, Wei CC, Ransom RF, Benndorf R, Smoyer WE. Dose- and time-dependent glucocorticoid receptor signaling in podocytes. American Journal of Physiology - Renal Physiology 2010;299(4):F845-53. [MEDLINE: 20630936]
118. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
119. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
120. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analysis of randomized trials of health care interventions. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No: MR000010. [DOI: 10.1002/14651858.MR000010.pub3]
121. Hyams JS, Carey DE. Corticosteroids and growth. Journal of Pediatrics 1988;113(2):249-54. [MEDLINE: 3294360]
122. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatrics 2008;45(3):203-14. [MEDLINE: 18367765]
123. Abramowicz M, Barnett HL, Edelmann CM Jr, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome: A report for the International Study of Kidney Disease in Children. Lancet 1970;1(7654):959-61. [MEDLINE: 4191931]
124. Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984;73(4):497-501. [MEDLINE: 6709428]
125. Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends in Pharmacological Sciences 2013;34(9):518-30. [MEDLINE: 23953592]
126. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatric Nephrology 2013;28(3):415-26. [MEDLINE: 23052651]
127. Rovin BH, Caster DJ, Catran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019;95(2):281-295. [MEDLINE: 30665569]
128. Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney International 2005;68(3):1275-81. [MEDLINE: 16105061]
129. Kirschke E, Goswami D, Southworth D, Griffin PR, Agard D. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaparone cycles. Cell 2014;157(7):1685-97. [MEDLINE: 24949977]
130. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Archives of Disease in Childhood 1982;57(7):544-8. [MEDLINE: 7103547]
131. Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No: CD002290. [DOI: 10.1002/14651858.CD002290.pub5]
132. MacHardy N, Miles PV, Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatric Nephrology 2009;24(11):2193-201. [MEDLINE: 19672630]
133. Mishra OM, Basu B, Upadhyay SK, Prasad R, Schaefer F. Behavioural abnormalities in children with nephrotic syndrome. Nephrology Dialysis Transplantation 2010;25(8):2537-41. [MEDLINE: 20200003]
134. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352(9128):609-13. [MEDLINE: 9746022]
135. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285(15):1992-5. [MEDLINE: 11308436]
136. Neuhaus TJ, Langlois V, Licht C. Behavioural abnormalities in children with nephrotic syndrome--an underappreciated complication of a standard treatment? Nephrology Dialysis Transplantation 2010;25(8):2397-9. [MEDLINE: 20573807]
137. Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS. Ocular complications of paediatric patients with nephrotic syndrome. Clinical & Experimental Ophthalmology 2001;29(4):239-43. [MEDLINE: 11545423]
138. Niaudet P. Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(10):1457-8. [MEDLINE: 19808239]
139. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018;392(10141):61-74. [MEDLINE: 29910038]
140. Ohashi T, Uchida K, Uchida S, Sasaki S, Nitta K. Dexamethasone increases the phosphorylation of nephrin in cultured podocytes. Clinical & Experimental Nephrology 2011;15(5):688-93. [MEDLINE: 21695412]
141. Ponticelli C, Locatelli F. Glucocorticoids in the treatment of glomerular diseases. Clinical Journal of The American Society of Nephrology: CJASN 2018;13(5):815-22. [MEDLINE: 29475991]
142. Raja K, Parikh A, Webb H, Hothi D. Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children. Pediatric Nephrology 2017;32(2):99-105. [MEDLINE: 27677978]
143. Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheumatic Diseases Clinics of North America 2016;42(1):15-31. [MEDLINE: 26611548]
144. Rüth EM, Kemper M, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid sensitive nephrotic syndrome come of age: long-term outcome. Journal of Pediatrics 2005;147(2):202-7. [MEDLINE: 16126050]
145. Samuel S, Morgan CJ, Bitzan N, Mammen C, Dart AB, Manns BJ, et al. Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatric Nephrology 2013;28(12):2289-98. [MEDLINE: 23917450]
146. Schijvens AM, ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology 2019;34(3):389-403. [MEDLINE: 29549463]
147. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387]
148. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
149. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
150. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. Journal of the American Society of Nephrology 1997;8(5):769-76. [MEDLINE: 9176846]
151. Vivarelli M, Massella l, Ruggiero B, Emma F. Minimal change disease. Clinical Journal of The American Society of Nephrology: CJASN 2017;12(2):332-45. [MEDLINE: 27940460]
152. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No: CD001533. [DOI: 10.1002/14651858.CD001533.pub5]
153. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Archives of Disease in Childhood 2000;83(1):45-51. [MEDLINE: 10868999]
154. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD001533. [DOI: 10.1002/14651858.CD001533]
155. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No: CD001533. [DOI: 10.1002/14651858.CD001533.pub2]
156. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No: CD001533. [DOI: 10.1002/14651858.CD001533.pub3]
157. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No: CD001533. [DOI: 10.1002/14651858.CD001533.pub4]